Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T53524
|
||||
Former ID |
TTDC00311
|
||||
Target Name |
Alpha platelet-derived growth factor receptor
|
||||
Gene Name |
PDGFRA
|
||||
Synonyms |
CD140a antigen; PDGF-R-alpha; Platelet-derived growth factor receptor alpha; PDGFRA
|
||||
Target Type |
Successful
|
||||
Disease | Cancer [ICD9: 140-229; ICD10: C00-C96] | ||||
Gastrointestinal cancers [ICD9: 150-159; ICD10: C15-C26] | |||||
Glioblastoma multiforme [ICD9: 191; ICD10: C71] | |||||
Non-small cell lung cancer; Ovarian cancer [ICD9:183; ICD10: C33-C34, C56] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Soft tissue sarcoma [ICD9: 171; ICD10: C00-D49] | |||||
Function |
Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor.
|
||||
BioChemical Class |
Kinase
|
||||
Target Validation |
T53524
|
||||
UniProt ID | |||||
EC Number |
EC 2.7.10.1
|
||||
Sequence |
MGTSHPAFLVLGCLLTGLSLILCQLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYP
MSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIY VPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNG TFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNN EVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVK EMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENL TEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDL VDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRD RSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSELTVAAAVLVLLVIVII SLIVLVVIWKQKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLG SGAFGKVVEGTAYGLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNL LGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHHPEKPKKELDIFGLNPADESTRSY VILSFENNGDYMDMKQADTTQYVPMLERKEVSKYSDIQRSLYDRPASYKKKSMLDSEVKN LLSDDNSEGLTLLDLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLA RDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGILLWEIFSLGGTPYPGMM VDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKK SYEKIHLDFLKSDHPAVARMRVDSDNAYIGVTYKNEEDKLKDWEGGLDEQRLSADSGYII PLPDIDPVPEEEDLGKRNRHSSQTSEESAIETGSSSSTFIKREDETIEDIDMMDDIGIDS SDLVEDSFL |
||||
Drugs and Mode of Action | |||||
Drug(s) | Olaratumab | Drug Info | Approved | Soft tissue sarcoma | [889440] |
CP-868596 | Drug Info | Phase 3 | Gastrointestinal cancers | [542807], [547352] | |
E-3810 | Drug Info | Phase 3 | Solid tumours | [524749], [542632] | |
Famitinib | Drug Info | Phase 2 | Cancer | [532104], [542811] | |
MEDI-575 | Drug Info | Phase 2 | Glioblastoma multiforme | [551134] | |
MP470 | Drug Info | Phase 2 | Solid tumours | [531617], [532785], [542847] | |
XL-820 | Drug Info | Phase 2 | Solid tumours | [522178] | |
Olaratumab | Drug Info | Phase 1 | Non-small cell lung cancer; Ovarian cancer | [525103] | |
SRI-62-834 | Drug Info | Discontinued in Phase 2 | Solid tumours | [544742] | |
CEP-2563 | Drug Info | Discontinued in Phase 1 | Solid tumours | [546416] | |
AG1295 | Drug Info | Terminated | Discovery agent | [541205], [546396] | |
RG-13022 | Drug Info | Terminated | Discovery agent | [544752] | |
Inhibitor | (1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone | Drug Info | [528209] | ||
(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone | Drug Info | [528209] | |||
(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone | Drug Info | [528209] | |||
(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone | Drug Info | [528209] | |||
(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone | Drug Info | [528209] | |||
1-Phenyl-1H-benzoimidazol-5-ol | Drug Info | [534808] | |||
1-Phenyl-1H-benzoimidazole | Drug Info | [534808] | |||
3-((E)-Styryl)-quinoline | Drug Info | [533862] | |||
3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline | Drug Info | [533862] | |||
3-(1H-Indol-3-yl)-quinoline | Drug Info | [533862] | |||
3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline | Drug Info | [533862] | |||
3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline | Drug Info | [533862] | |||
3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline | Drug Info | [533862] | |||
3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline | Drug Info | [533862] | |||
3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline | Drug Info | [533862] | |||
3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline | Drug Info | [533862] | |||
3-Benzyloxy-6,7-dimethoxy-quinoline | Drug Info | [533862] | |||
3-Cyclohexylethynyl-6,7-dimethoxy-quinoline | Drug Info | [533862] | |||
3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline | Drug Info | [533862] | |||
3-Cyclopentyl-6,7-dimethoxy-quinoline | Drug Info | [533862] | |||
3-Pyridin-3-yl-quinoline-6,7-diol | Drug Info | [533862] | |||
3-Pyridin-4-yl-quinolin-7-ol | Drug Info | [533872] | |||
3-Pyridin-4-yl-quinoline | Drug Info | [533872] | |||
3-Pyridin-4-yl-quinoline-5,7-diol | Drug Info | [533872] | |||
3-Thiophen-3-yl-quinoline | Drug Info | [533862] | |||
4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline | Drug Info | [551331] | |||
4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine | Drug Info | [525530] | |||
4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid | Drug Info | [533862] | |||
4-(6,7-Dimethoxy-quinolin-3-yl)-phenol | Drug Info | [533862] | |||
4-Benzoimidazol-1-yl-phenylamine | Drug Info | [534808] | |||
5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol | Drug Info | [527769] | |||
5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline | Drug Info | [533872] | |||
5,7-Dimethoxy-3-pyridin-4-yl-quinoline | Drug Info | [533872] | |||
5,7-Dimethoxy-3-thiophen-3-yl-quinoline | Drug Info | [533862] | |||
5,7-Dimethyl-3-thiophen-3-yl-quinoline | Drug Info | [533862] | |||
5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one | Drug Info | [533862] | |||
5-Fluoro-3-thiophen-3-yl-quinoline | Drug Info | [533862] | |||
5-Methoxy-1-phenyl-1H-benzoimidazole | Drug Info | [534808] | |||
6,7-Dichloro-3-thiophen-3-yl-quinoline | Drug Info | [533862] | |||
6,7-Difluoro-3-thiophen-3-yl-quinoline | Drug Info | [533862] | |||
6,7-Dimethoxy-3-((E)-styryl)-quinoline | Drug Info | [533862] | |||
6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline | Drug Info | [533862] | |||
6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline | Drug Info | [533862] | |||
6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline | Drug Info | [533862] | |||
6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline | Drug Info | [533862] | |||
6,7-Dimethoxy-3-p-tolyl-quinoline | Drug Info | [533862] | |||
6,7-Dimethoxy-3-phenyl-quinoline | Drug Info | [533862] | |||
6,7-Dimethoxy-3-phenylethynyl-quinoline | Drug Info | [533862] | |||
6,7-Dimethoxy-3-pyridin-3-yl-quinoline | Drug Info | [533862] | |||
6,7-Dimethoxy-3-pyridin-4-yl-quinoline | Drug Info | [533872] | |||
6,7-Dimethoxy-3-thiophen-2-yl-quinoline | Drug Info | [533862] | |||
6-Methoxy-3-pyridin-4-yl-quinoline | Drug Info | [533872] | |||
6-Methoxy-3-thiophen-3-yl-quinoline | Drug Info | [533862] | |||
7-Chloro-3-pyridin-4-yl-quinoline | Drug Info | [533872] | |||
7-Fluoro-3-thiophen-3-yl-quinoline | Drug Info | [533862] | |||
7-Methoxy-3-pyridin-4-yl-quinoline | Drug Info | [533872] | |||
7-Methoxy-3-thiophen-3-yl-quinoline | Drug Info | [533862] | |||
7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline | Drug Info | [533862] | |||
AG1295 | Drug Info | [528209] | |||
Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine | Drug Info | [533862] | |||
Bis-(5-hydroxy-1H-indol-2-yl)-methanone | Drug Info | [528209] | |||
BMS-536924 | Drug Info | [527711] | |||
CEP-2563 | Drug Info | [527155] | |||
compound 8h | Drug Info | [531471] | |||
compound 8h | Drug Info | [531959] | |||
CP-673451 | Drug Info | [527429] | |||
D-65476 | Drug Info | [526272] | |||
Di(1H-indol-2-yl)methanone | Drug Info | [528209] | |||
E-3810 | Drug Info | [525382] | |||
Famitinib | Drug Info | [532104] | |||
JNJ-10198409 | Drug Info | [527932] | |||
PD-0166326 | Drug Info | [525862] | |||
PD-0173952 | Drug Info | [525862] | |||
PD-0173955 | Drug Info | [525862] | |||
PD-0173956 | Drug Info | [525862] | |||
PD-0173958 | Drug Info | [525862] | |||
PD-0179483 | Drug Info | [525862] | |||
PD-0180970 | Drug Info | [525862] | |||
PP121 | Drug Info | [529744] | |||
RG-13022 | Drug Info | [533862] | |||
Ro-4396686 | Drug Info | [528018] | |||
RPR-101511 | Drug Info | [533862] | |||
RPR-108514A | Drug Info | [551338] | |||
SEMAXINIB | Drug Info | [526575] | |||
SRI-62-834 | Drug Info | [533360] | |||
SU-11652 | Drug Info | [526575] | |||
XL-820 | Drug Info | [550402] | |||
Modulator | CP-868596 | Drug Info | |||
MP470 | Drug Info | [531617], [532785] | |||
Olaratumab | Drug Info | [532640] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
Pathways | |||||
KEGG Pathway | MAPK signaling pathway | ||||
Ras signaling pathway | |||||
Rap1 signaling pathway | |||||
Calcium signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
Focal adhesion | |||||
Gap junction | |||||
Regulation of actin cytoskeleton | |||||
HTLV-I infection | |||||
Pathways in cancer | |||||
MicroRNAs in cancer | |||||
Glioma | |||||
Prostate cancer | |||||
Melanoma | |||||
Central carbon metabolism in cancer | |||||
Choline metabolism in cancer | |||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
PDGF signaling pathway | |||||
Pathway Interaction Database | ATF-2 transcription factor network | ||||
PDGFR-alpha signaling pathway | |||||
PDGF receptor signaling network | |||||
Reactome | PIP3 activates AKT signaling | ||||
Constitutive Signaling by Aberrant PI3K in Cancer | |||||
RAF/MAP kinase cascade | |||||
WikiPathways | Regulation of Actin Cytoskeleton | ||||
Osteoblast Signaling | |||||
Focal Adhesion | |||||
Organogenesis (Part 2 of 3) | |||||
PIP3 activates AKT signaling | |||||
Cardiac Progenitor Differentiation | |||||
Integrated Pancreatic Cancer Pathway | |||||
Allograft Rejection | |||||
Signaling Pathways in Glioblastoma | |||||
Signaling by PDGF | |||||
Angiogenesis | |||||
References | |||||
Ref 522178 | ClinicalTrials.gov (NCT00570635) A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib. U.S. National Institutes of Health. | ||||
Ref 524749 | ClinicalTrials.gov (NCT02135107) A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients. U.S. National Institutes of Health. | ||||
Ref 525103 | ClinicalTrials.gov (NCT02377752) A Study of Olaratumab in Japanese Participants With Advanced Cancer. U.S. National Institutes of Health. | ||||
Ref 531617 | The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol. 2011 Oct;101(1):59-65. | ||||
Ref 532104 | Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. | ||||
Ref 532785 | Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204. | ||||
Ref 541205 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5914). | ||||
Ref 542632 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7649). | ||||
Ref 542807 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7882). | ||||
Ref 542811 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7886). | ||||
Ref 542847 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7932). | ||||
Ref 544742 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000818) | ||||
Ref 544752 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000854) | ||||
Ref 546396 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007894) | ||||
Ref 546416 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007988) | ||||
Ref 525382 | E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. doi: 10.1158/0008-5472.CAN-10-2700. Epub 2011 Jan 6. | ||||
Ref 525530 | J Med Chem. 1999 Jul 1;42(13):2373-82.Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor. | ||||
Ref 525862 | Biochem Pharmacol. 2000 Oct 1;60(7):885-98.Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. | ||||
Ref 526272 | Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase. J Med Chem. 2002 Feb 28;45(5):1002-18. | ||||
Ref 526575 | J Med Chem. 2003 Mar 27;46(7):1116-9.Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. | ||||
Ref 527155 | Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov;22(4):449-58. | ||||
Ref 527429 | Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. 2005 Feb 1;65(3):957-66. | ||||
Ref 527711 | J Med Chem. 2005 Sep 8;48(18):5639-43.Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. | ||||
Ref 527769 | J Med Chem. 2005 Oct 6;48(20):6194-201.Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. | ||||
Ref 527932 | J Med Chem. 2005 Dec 29;48(26):8163-73.(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. | ||||
Ref 528018 | Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. Epub 2006 Feb 3.Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. | ||||
Ref 528209 | J Med Chem. 2006 Jun 1;49(11):3101-15.Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. | ||||
Ref 529744 | Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. | ||||
Ref 531471 | Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8. | ||||
Ref 531617 | The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol. 2011 Oct;101(1):59-65. | ||||
Ref 531959 | The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. | ||||
Ref 532104 | Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. | ||||
Ref 532640 | A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604. | ||||
Ref 532785 | Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204. | ||||
Ref 533360 | Antitumor activity of SRI 62-834, a cyclic ether analog of ET-18-OCH3. Lipids. 1987 Nov;22(11):884-90. | ||||
Ref 533862 | J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. | ||||
Ref 533872 | J Med Chem. 1994 Aug 19;37(17):2627-9.5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase. | ||||
Ref 534808 | J Med Chem. 1998 Dec 31;41(27):5457-65.Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.